MIB2 KO markedly restricted tumor growth and improved survival rate when combined with either PD-L1 or CTLA4 mAb (Supplemental Figure 5, B and D), but no mice survived more than 50 days after tumor inoculation. The gene discussed is CTLA4; the disease is neoplasm.